Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Nab-paclitaxel
Nab-paclitaxel/m^2 · 1 trial · 3 indications
Time from randomization until the time of first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause, whichever occurs first
Time from randomization to death by any cause
| Arm | Type | Description |
|---|---|---|
| Nab-paclitaxel 80 mg/m^2 with Relacorilant 150 mg | EXPERIMENTAL | Patients receive nab-paclitaxel 80 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle in combination with intermittent relacorilant (150 mg relacorilant once daily on the day before, the day of, and the day after nab-paclitaxel), administered orally under fed conditions. Relacorilant will not be administered on Cycle 1 Day -1. |
| Nab-paclitaxel 100 mg/m^2 | ACTIVE_COMPARATOR | Patients receive nab-paclitaxel 100 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle. |
| Name | Type | Description |
|---|---|---|
| Nab-paclitaxel 80 mg/m^2 | DRUG | Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle. |
| Relacorilant 150 mg once daily (QD) | DRUG | Relacorilant is administered as capsules for oral dosing. |
| Nab-paclitaxel 100 mg/m^2 | DRUG | Nab-paclitaxel is administered as IV infusion on Day 1, 8, and 15 of each 28-day cycle. |
Inclusion Criteria: * Signed and dated Institutional Review Board/Independent Ethics Committee-approved informed consent form prior to study-specific screening procedures. * Confirmed histologic diagnosis of high-grade (Grade 3) serous, epithelial ovarian, primary peritoneal, or fallopian tube carc...
Nab-paclitaxel/m^2 is being studied for the treatment of ovarian neoplasms, specifically advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer. It is an investigational small molecule in Phase 3 clinical development, and it is not yet approved by the FDA.
Nab-paclitaxel/m^2 is a small molecule that is being evaluated in combination with relacorilant. The specific molecular target of Nab-paclitaxel/m^2 is not disclosed in the available information, so its mechanism of action is not described here.
Nab-paclitaxel/m^2 is being developed by Corcept Therapeutics Incorporated, a company traded on the NASDAQ under the ticker symbol CORT. The drug is currently in Phase 3 clinical trials for ovarian cancer.
Nab-paclitaxel/m^2 is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 3 trial is active but not recruiting participants.
Nab-paclitaxel/m^2 is being studied in a Phase 3 trial with the identifier NCT05257408. This randomized, active-controlled trial enrolls 381 female participants aged 18 years and older with advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer. The trial is active but not recruiting.
Yes, Nab-paclitaxel/m^2 is also known as Nab-paclitaxel 80 mg/m^2 and Nab-paclitaxel. These names refer to the same drug being developed by Corcept Therapeutics for the treatment of ovarian cancer.